• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At Baxter International (BAX) Valuation As CFO Transition Draws Investor Attention

    Simply Wall St·03/27/2026 06:14:52
    Listen to the news

    CFO transition puts Baxter International (BAX) under closer investor review

    The recent announcement that chief financial officer Joel Grade will depart Baxter International, with Anita Zielinski stepping in as interim CFO, has put fresh attention on how you assess the company’s financial leadership and stock.

    See our latest analysis for Baxter International.

    Baxter International’s share price has come under pressure recently, with a 30 day share price return of a 19.2% decline and a year to date share price return of a 14.5% decline. The 1 year total shareholder return of a 49.9% decline points to a longer period of fading momentum despite ongoing operational updates such as the CFO transition, index removal and upcoming virtual annual meeting.

    If this kind of reset has you thinking about where capital might work harder next, it could be worth scanning for healthcare names tied to AI trends through the 36 healthcare AI stocks

    With Baxter International valued at roughly US$8.8b, trading around US$16.67 per share and flagged with both a value score of 5 and an implied discount to some estimates, is this a reset opportunity or are markets already fully reflecting the outlook?

    Most Popular Narrative: 22.9% Undervalued

    With Baxter International last closing at $16.67 and the most followed narrative pointing to a fair value of $21.63, the gap between price and modelled worth is clear and invites a closer look at what is driving that view.

    Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.

    Read the complete narrative.

    Want to see what sits behind that margin story and fair value gap? The narrative leans heavily on steady revenue progress, improving profitability and a higher future earnings multiple tied to those shifts.

    Result: Fair Value of $21.63 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the fair value gap relies on hospital volume recovery and margin improvement, and setbacks around Novum IQ quality issues or stranded cost cuts could quickly challenge that story.

    Find out about the key risks to this Baxter International narrative.

    Next Steps

    With sentiment clearly mixed, and with both risks and potential rewards in play, it makes sense to quickly review the full picture and weigh it for yourself using the 3 key rewards and 1 important warning sign

    Looking for more investment ideas?

    If Baxter has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover more targeted ideas that fit your goals and risk comfort.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.